Kardigan, Inc. (KARD)
NASDAQ: KARD · Real-Time Price · USD
14.46
-1.98 (-12.04%)
Sep 23, 2026, 3:11 PM EDT - Market open
Kardigan Earnings Call Transcripts
Fiscal Year 2026
-
A platform-focused cardiovascular innovator highlighted its late-stage pipeline in genetic cardiomyopathy and aortic stenosis, leveraging adaptive trial designs and real-world data integration. Key programs danicamtiv and ataciguat are advancing through pivotal trials, with major data readouts expected next year.